Robert Carpenter

Part of Sanofi, IG Laboratories, Inc. is a company that provides genetic testing services. The company is based in Framingham, MA. The company was founded by Peter L. Lanciano. IG Laboratories was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on October 03, 1995 for $21 million.

GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA.

Cardiac has developed RHYTHMx ECD, technology that continuously monitors a patient's heart rhythm and provided defibrillation to help the organ keep a steady beat. Cardiac Science has used the technology to develop an external cardiac defibrillator, the Powerheart, which is used in hospitals. The firm also sold patient monitors and emergency defibrillators, and has developed a small portable defibrillator that can be used by patients in the hospital or at home. Cardiac Science markets its products in more than 50 countries worldwide.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Procept is engaged in the research and development of small molecule therapeutics for the prevention and treatment of chronic and life-threatening immune system disorders. Procept is developing therapeutics for the treatment of autoimmune disease, organ transplant rejection and infectious diseases, such as AIDS and tuberculosis. The company is located in San Diego. CA

Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products.

Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA.

Founded in 1994 by Robert J. Carpenter, Boston Medical Investors, Inc. is a privately-held venture capital firm located in Cambridge, Massachusetts.